Delving into the Latest Updates on Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Endocrinology and Metabolic Disease

Nervous System Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	3
Endocrinology and Metabolic Disease	3
Neoplasms	3
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6
Chemical drugs	1

Top 5 Target	Count

D2 receptor(Dopamine D2 receptor)	1
GABAA receptor(Gamma-aminobutyric acid A receptor)	1
CDK6 x DYRK2	1
PARP(Poly (ADP-Ribose) polymerase)	1
ACE x ACE2 x NCC	1

本试验旨在研究单次空腹和餐后口服江苏天士力帝益药业有限公司研制、生产的波生坦分散片（32 mg（以C27H29N5O6S计））的药代动力学特征；以Actelion Pharmaceuticals Ltd持证、Patheon Inc.生产的波生坦分散片（Tracleer®，32 mg（以C27H29N5O6S计））为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of bosentan dispersible tablets (32 mg (calculated as C27H29N5O6S)) developed and produced by Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using bosentan dispersible tablets (Tracleer®, 32 mg (calculated as C27H29N5O6S)) licensed by Actelion Pharmaceuticals Ltd and produced by Patheon Inc. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Start Date18 Sep 2024

Sponsor / Collaborator

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

CTR20241348 / CompletedNot Applicable

富马酸伏诺拉生片人体生物等效性研究

[Translation] Study on the bioequivalence of vonoprazan fumarate tablets in healthy volunteers

本试验旨在研究单次空腹和餐后口服江苏天士力帝益药业有限公司研制、生产的富马酸伏诺拉生片（20 mg）的药代动力学特征；以Takeda Pharmaceutical Company Limited, Hikari Plant生产的富马酸伏诺拉生片（沃克®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of vonoprazan fumarate tablets (20 mg) developed and produced by Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal. Vonoprazan fumarate tablets (Walker®, 20 mg) produced by Takeda Pharmaceutical Company Limited, Hikari Plant was used as the reference preparation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date18 Apr 2024

Sponsor / Collaborator

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

CTR20222440 / CompletedNot Applicable

巴氯芬口服溶液在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验

[Translation] A human bioequivalence clinical trial of baclofen oral solution in Chinese healthy subjects after single administration under fasting and fed conditions

主要目的：以持证商为Novartis Pharmaceuticals UK Ltd的巴氯芬口服溶液（商品名：Lioresal®）为参比制剂，以江苏天士力帝益药业有限公司研发的巴氯芬口服溶液为受试制剂，通过单中心、随机、开放、单次给药、两制剂、两周期、两序列、交叉设计的临床试验来评价两种制剂在中国健康受试者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the two preparations in fasting and fed state in healthy Chinese subjects by using the baclofen oral solution (trade name: Lioresal®) of Novartis Pharmaceuticals UK Ltd as the reference preparation and the baclofen oral solution developed by Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. as the test preparation through a single-center, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, crossover design clinical trial. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date08 Oct 2022

Sponsor / Collaborator

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

100 Clinical Results associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Login to view more data

20

Literatures (Medical) associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

01 Feb 2024·Bioorganic & Medicinal Chemistry

Development of tenofovir monobenzyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment

Article

Author: Zhou, Shuiping ; Wang, Chunjian ; Cai, Jinyong ; Sun, Xizheng ; Tang, Hai ; Ding, Aizhong ; Lin, Ling ; Song, Li ; Ma, Xiaohui

Various tenofovir (TFV) prodrugs have been developed by introducing masking groups to the hydroxyls of the monophosphonate group to enhance intestinal absorption efficiency and therapeutic effects. However, the reported TFV prodrugs have drawbacks such as low bioavailability, systemic toxicity caused by their breakdown in non-targeted tissues, and potential low intracellular conversion efficiency. In the present study, we developed a class of TFV monobenzyl ester phosphonoamidate prodrugs without substitutions on the benzene ring. Compared with previous TFV prodrugs, compounds 3a and 3b developed in the present study showed higher anti-hepatitis B virus activity, stronger stability and higher levels of intrahepatic enrichment of the metabolic product (TFV), indicating the potential of these compounds as novel prodrugs with high efficiency and low systemic toxicity for the treatment of hepatitis B.

01 Sep 2021·Synthesis

Synthesis of Dibenzyls by Nickel-Catalyzed Homocoupling of Benzyl Alcohols

Author: Guo, Peng ; Shu, Xing-Zhong ; Huang, Xiaochuang ; Pan, Feng-Feng

AbstractDibenzyls are essential building blocks that are widely used in organic synthesis, and they are typically prepared by the homocoupling of halides, organometallics, and ethers. Herein, we report an approach to this class of compounds using alcohols, which are more stable and readily available. The reaction proceeds via nickel-catalyzed and dimethyl oxalate assisted dynamic kinetic homocoupling of benzyl alcohols. Both primary and secondary alcohols are tolerated.

Guangdong Huagong

Determination of Methanol and Ethanol in Sulpiride by GC

Author: Liang Zhongwei ; Ren Gan ; Wang Lan ; Zhang Wenkai

Objective: To establish a GC method to determination of methanol and ethanol in sulpiride.Methods: The A DB-624 column(30 m*0.53 mm*3.0 μm)(temperature programming), nitrogen as carrier gas(flow rate: 4.0 m L·min∼(-1)) and FID detector(temperature: 250 °C) were used.Injection port temperature was140 °C, injection volume was 1 μL and the split ratio was 5:1.Results: The calibration curves were well linear for methanol and ethanol in the range of 2.068∼310.2μg/m L(r=0.999) and 24.132∼619.8 μg/m L(r=0.999), resp.The recovery of methanol and ethanol were 99.7 %(RSD=0.63 %) and 100.8 %(RSD=0.83 %), resp.Conclusion: The method is sensitive, accurate, precise and reliable to determine of methanol and ethanol in sulpiride, which is superior to other methods, and good for improving the safety of drug.

100 Deals associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 2 Clinical

Approved

5

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Minodronic Acid Hydrate ( FDPS )	Osteoporosis, Postmenopausal More	Approved
Hydrochlorothiazide/Lisinopril ( ACE x ACE2 x NCC )	Hypertension More	Approved
Tiapride Hydrochloride ( D2 receptor )	Parkinson Disease More	Approved
Eszopiclone ( GABAA receptor )	Sleep Initiation and Maintenance Disorders More	Approved
Temozolomide ( DNA )	Glioblastoma More	Approved